OasisLMS

The Importance of Molecular Tumor Boards in Oncologic Practice is a comprehensive, interactive e-learning course developed by the International Association for the Study of Lung Cancer (IASLC) and grounded in the IASLC Molecular Tumor Board consensus publication. Designed for an international, multidisciplinary audience, the course examines how Molecular Tumor Boards (MTBs) support the interpretation of complex molecular data and enable personalized, evidence-based cancer care. Through expert guidance, real-world case scenarios, and practical tools, learners explore MTB structure, workflows, reporting standards, and future directions, with applicability across diverse global practice settings.

Enduring Activity Launch Date: January 20, 2026
Enduring Activity Expiration Date: January 19, 2027

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician associates.

Upon completion of this educational activity, participants should be able to: 

• Navigate complex advances in molecular testing and targeted therapy.
• Examine the key features and composition of molecular tumor boards. 
• Explore how molecular tumor boards work with a framework for implementation.
• Interpret and develop molecular tumor board reports.
• Participate in interactive molecular tumor board scenarios.
• Evaluate challenges, opportunities, and future perspectives. 

• Rasha Aboelhassan, MD, Senior Oncology Consultant, Nasser Institute Hospital for Research and Treatment, Cairo, Egypt
• Mihaela Aldea, MD, PhD, Medical Oncologist, Institut Gustave Roussy, Villejuif, France
• Matthew Hatton, MBChB, MSc, FRCP, Radiation Oncologist, Honorary Professor, Sheffield Teaching Hospitals NHS Foundation Trust, University of Sheffield, Weston Park Hospital, Sheffield, UK
• Stefanie Houseknecht, PharmD, BCOP, Clinical Pharmacy Specialist, Thoracic Malignancies, Johns Hopkins Hospital and Bayview Medical Center, Baltimore, MD, USA
• Rina Hui, MBBS, PhD, FRACP, Director, Centre of Cancer Medicine, HKU Med, and Clinical Professor, University of Hong Kong
• Depali Jain, MD, Professor, Department of Pathology, AIIMS, New Delhi, India
• Jii Bum (Joy) Lee, MD, PhD, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
• Rami Manochakian, MD, FASCO, Associate Professor of Medicine, Consultant, Thoracic Oncology, Program Director, Hematology/Oncology Fellowship, Vice Chair, Education, Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Florida, Jacksonville, FL, USA
• Bartomeu Massuti, MD, Head, Medical Oncology Department, Alicante University Hospital, Alicante, Spain
• Bharathi Muthusamy, MD, Assistant Professor of Medicine, Department of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA
• Nick Pavlakis, MSc, MBBS, MMed (Clin. Epi), PhD, Professor of Medicine, University of Sydney, Senior Staff Specialist, Department of Medical Oncology, Royal North Shore Hospital, St. Leonards, Australia
• Norma Pilnik, MD, B.Pharm, MBA, PhD, Professor of Medicine, Academy Director of the Oncology Specialty, Cordoba, Argentina
• Gustavo Faibischew Prado, MD, PhD, Pulmonologist, Universidade de Sao Paulo, Brazil
• Luis E. Raez, MD, FASCO, FACP, Chief Scientific Officer and Medical Director, Memorial Cancer Institute/Memorial Health Care System, Pembroke Pines, FL, USA
• Jonathan Riess, MD, Director, Thoracic Oncology, UC Davis Cancer Center, Sacramento, CA, USA
• Christian Diego Rolfo, MD, PhD, Professor of Internal Medicine, Director Division of Medical Oncology, Associate Director for Early Clinical Trials, OSUCCC-James, The Arthur G. James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
• Stephanie Saw, MBBS, MMed, PhD, Consultant, Division of Medical Oncology, Assistant Professor, National Cancer Center, Singepore
• Telma Sequeira, MD, MSc, Instituto Portugues de Oncologia de Lisboa Francisco Gentil Martins, Lisbon, Portugal
• Aaron C. Tan, MBBS, PhD, FRACP, Medical Oncologist, National Cancer Centre, Singapore
• Lodovica Zullo, MD, Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Aaron Tan	1. AstraZeneca, Amgen, Pfizer	1. Advisor	Planner
Christian Diego Rolfo	1. Guardant, Foundation One COR2ED, HPM Education IDEOlogy Merck and Roche, OneCell Dx 2. Novocure, AstraZeneca, Imagene, MedStar, Amgen, Boehringer-Ingelheim, Hoffmann-La Roche Ltd, Janssen Pharmaceutical, NeoGenomics , Pfizer, Inc. and Regeneron; AIRC 3. Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO)	1. Research (Funding paid to institution) 2. Advisor 3. External Advisor	Planner
Gustavo Prado	1. AstraZeneca, Bristol Myers Squibb, Sanofi-Aventis	1. Reseach (Funding paid to institution)	Planner
Jonathan Riess	1. Summit, Nuvalent, Merck, Boehringer Ingelheim, AstraZeneca, Novartis, ArriVent, Revolution Medicines, IO Biotech 2. Boehringer Ingelheim, BMS, Roche/Genentech, Daiichi Sankyo, Regeneron, Janssen, Merus NV, Amgen, Catalyst, SeaGen/Pfizer, Bicycle Therapeutics, ArriVent	1. Research (Funding paid to institution) 2. Consultant	Planner
Luis E. Raez	1. bms, astra-zeneca, abbie, bayer, genetech, johnson&johnson, merck, pfizer, natera, guardant health, Lilly Oncology 2. bms, astra-zeneca, abbie, bayer, johnson&johnson, merck, pfizer, natera	1. Research (Funding paid to institution) 2. Consultant	Planner
Mihaela Aldea	1. Amgen, Sandoz, Owkin, AstraZeneca	1. Research (Funding paid to institution)	Planner
Nick Pavlakis	1. Bayer, Pfizer, Roche 2. BI, MSD,  Merck, BMS,  Astra Zeneca, Takeda, Pfizer, Roche, Amgen, Beigene, Gilead, Zymeworks, BioNTech, Daiichi, DUO Oncology, Amplia, Johnson and Johnson, RACE oncology	1. Research (Funding paid to instiution) 2. Advisor	Planner
Rami Manochakian	1. BMS, Astrazeneca, Janssen, Oncohost, Abbvie, Daiichi Sankyo, Novocure	1. Advisor	Planner
Rina Hui	1. Amgen, AstraZeneca, Chugai Pharma China, MSD, Novartis, Olema, Relay Therapeutics, Roche 2. Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Janssen, Johnson & Johnson, Merck, MSD, Novartis, Roche, Takeda, Zai Lab	1. Research (Funding paid to institution) 2. Advisor
Stefanie Houseknecht	1. AstraZeneca, Daiichi Sankyo	1. Consultant	Planner
Telma Sequeira	1. J&J; MSD; BMS; Takeda; Astra-Zeneca; Merck; Pfizer; Roche; Lilly; Daiichi-Sankyo	1. Advisor	Planner

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Study of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationships to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Associates
The National Commission on Certification of Physician Associates (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Successful Completion
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

• 1.5 MOC point in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program; and
• 1.5 MOC point in the American Board of Pathology (ABPath) Continuing Certification program (Lifelong Learning (CME)
• 1.5 MOC point (Self Assessment) in the American Board of Thoracic Surgery (ABTS) Maintenance of Certification (MOC) program

It is the CME Activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation. 

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians. 

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Live Activity Credit

To successfully earn credit, participants must complete the activity during the valid credit period that is notes on the title page. Follow these steps to earn CME/CE Credit*

1. Read about the target audience, learning objectives, and author disclosures.
2. Participate in the activity.
3. Complete the activity evaluation to provide feedback for future programs and receive credit.

Enduring Activity Credit

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test. Follow these steps to earn CME/CE credit*:

1. Read about the target audience, learning objectives, and author disclosures.

2. Study the educational content online or print it out, if applicable.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
4. Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.